



26th July 2016

www,clinicabaviera,com www,grupobaviera,es








	1H2016	1H2015	16-15
Revenues	47,521	42,262	12.4%
Spain	35,347	31,307	12.9%
International	12,174	10,955	11.1%
EBITDA	9,680	5,429	78.3%
Spain	7,694	4,918	56.5%
International	1,986	511	288.9%
Profit for the period	5,260	2,042	157.7%


2016	Q1	Q2	Q3	Q4	2015
Revenues	24,299	23,222			47,521
EBITDA	5,219	4,462			9,680
% 16-15	Q1	Q2	Q3	Q4	2016
Revenues	11.6%	13.3%			12.4%
EBITDA	56.8%	112.4%			78.3%





Consolidated Results

1H2016 Results






	2016	2015	Dif. 000	Dif. %
Net Revenues	47,521	42,262	5,259	12.4%
Operating expenses	(37,841)	(36,833)	1,007	2.7%
EBITDA	9,680	5,429	4,252	78.3%
D&A	(2,391)	(2,516)	(125)	(5.0%)
EBIT	7,289	2,913	4,377	150.3%
Financial Result	(153)	(23)	130	567.0%
Profit before taxes	7,136	2,889	4,247	147.0%
Corporate income tax	(1,876)	(846)	1,030	121.7%
Result for the period	5,260	2,042	3,219	157.7%



Headcount	Spain	International	Total
Branch managers	22	10	32
Doctors	129	39	168
Medical Support	425	166	591
Headquarters	54	24	78
Headcount	630	239	869

	Clinics
Spain	49
Germany & Austria	20
Italy	4
Clinics	73





CAPEX

	CAPEX
Maintenance	2,125
Openings	479
CAPEX	2,604

Net Cash Position

Net Cash Position	30/06/2016	31/12/2015	'000
Cash and equivalents	15,690	12,767	2,923
Financial debt (long and short term)	(13,776)	(13,915)	139
Earn outs	(115)	(225)	110
Net Cash Position	1,799	(1,373)	3,172



	:			
	2016	2015	'000	%
Property, plant and equipment	16,685	16,477	208	1.3%
Goodwill and other intangible assets	13,195	13,085	110	0.8%
Financial instruments and deferred taxes	1,865	2,156	(291)	(13.5%)
Debtors and other current assets	2,272	1,895	377	19.9%
Cash and equivalents (A) (*)	15,690	12,767	2,923	22.9%
Assets	49,707	46,380	3,327	7.2%
Loans and borrowings (B)	13,776	13,915	(139)	(1.0%)
Trade creditors and other financial liabilities	7,403	7,710	(307)	(4.0%)
Deferred payments(C)	115	225	(110)	(48.9%)
Tax payables	3,755	2,736	1,019	37.2%
Other current and non current liabilities	701	481	220	45.7%
Net equity	23,849	21,071	2,778	13.2%
Minority interests	108	242	(134)	(55.4%)
Equity and liabilities	49,707	46,380	3,327	7.2%
Net cash position(A-B-C)	(1,799)	1,373		
Dividends	(2,477)	(2,137)		
(*) Includes cash and other temporary financial investm	ents			

	2016
Profit before Taxes	7,136
D&A	2,391
Changes in Working Capital	(803)
Corporate income tax paid	(583)
Other adjustment to the result	192
Cash Flow from Operations	8,333
Purchase of Property, Plant and Equipment	(2,604)
Other Investing Flow	(87)
Cash Flow used in Investing	(2,691)
Charge for bank loans "received"	2,000
Payment on bank loans "returned"	(2,140)
Dividends Payment	(2,477)
Other Financing Flow	(102)
Cash flow used in Financing	(2,719)
Net change in cash position	2,923





Business Units Results



1H2016-1H2015	Spain	International	Total	
Net Revenues	35,347	12,174	47,521	
Operating Expenses	(27,653)	(10,188)	(37,841)	
1H2016 EBITDA	7,694	1,986	9,680	
EBITDA Margin 1H2016 %	21.8%	16.3%	20.4%	
1H2015 EBITDA	4,918	511	5,429	
000 16-15	2,776	1,476	4,252	



1H2016-1H2015	2016	%	2015	%	'000	%
Net Revenues	35,347		31,307		4,040	12.9%
Operating Expenses	(27,653)	(78.2%)	(26,389)	(84.3%)	1,264	4.8%
EBITDA	7,694	21.8%	4,918	15.7%	2,776	56.5%
D&A	(1,488)	(4.2%)	(1,655)	(5.3%)	(167)	(10.1%)
EBIT	6,206	17.6%	3,263	10.4%	2,943	90.2%





1H2016-1H2015	2016	%	2015	%	' 000	%
Net Revenues	12,174		10,955		1,219	11.1%
Operating Expenses	(10,188)	(83.4%)	(10,444)	(95.1%)	(256)	(2.5%)
EBITDA	1,986	16.3%	511	4.7%	1,476	288.9%
D&A	(903)	(7.4%)	(861)	(7.9%)	42	4.8%
EBIT	1,083	8.9%	(351)	(3.2%)	1,434	(408.9%)





Financial Calendar

October 2016 3Q2016 Results

Contact

IR Department

Paseo de la Castellana 20 28046 Madrid

Tel: +34 917 819 882/ 880

inversores@clinicabaviera,com; meperez@clinicabaviera,com

www.grupobaviera.es



The financial information contained in this document has been prepared in accordance with International Financial Reporting Standards (IFRS), This financial information is unaudited and, therefore, is subject to potential future changes,

This document is purely for informational purposes and does not constitute an offer or solicitation to sell, subscribe for or buy any securities, and neither this document nor anything contained herein shall form the basis of any contract or commitment,

This document may contain statements on intentions and estimates that constitute forward-looking statements in its general meaning, Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and other important factors that could cause actual developments or results to differ materially from those expressed in our forward looking statements, The Company assumes no obligation to publicly revise or update its forward-looking statements in the case of unexpected changes, events or circumstances that could affect them, Given the uncertainties of forward-looking statements, we caution readers not to place undue reliance on these statements,

For a discussion of these and other factors that may affect forward-looking statements and the Baviera Group's business, financial conditions and results of operations, see the documents and information of the Company filed with the *Comisión Nacional del Mercado de Valores* (Spanish Securities Exchange Commission)